Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

被引：6
|
作者：
Kerdivel, G. [1 ,2 ,3 ,4 ,5 ]
Chesnais, V. [1 ,2 ,3 ,4 ,6 ]
Becht, E. [4 ,7 ,8 ]
Toma, A. [9 ]
Cagnard, N. [10 ]
Dumont, F. [1 ,2 ,3 ,4 ,11 ]
Rousseau, A. [12 ]
Fenaux, P. [13 ]
Chevret, S. [14 ]
Chapuis, N. [1 ,2 ,3 ,4 ,6 ,12 ]
Boeva, V. [1 ,2 ,3 ,4 ,5 ]
Fridman, W. H. [4 ,7 ]
Fontenay, M. [1 ,2 ,3 ,4 ,6 ,12 ]
Kosmider, O. [1 ,2 ,3 ,4 ,6 ,12 ]
机构：
[1] Inst Cochin, Dept Dev, Reprod, Canc, Paris, France
[2] INSERM, U1016, Paris, France
[3] CNRS, UMR8104, Paris, France
[4] Univ Paris 05, Paris, France
[5] Team Computat Epigenet Canc, Paris, France
[6] Team Normal & Pathol Hematopoiesis Labeled Ligue, Paris, France
[7] INSERM UMR S1138, Canc Immune Controls & Escape, Cordeliers Res Ctr, Paris, France
[8] ASTAR, Singapore Immunol Network, Singapore, Singapore
[9] Hop Henri Mondor, AP HP, Serv Hematol Clin & Therapie Cellulaire, Creteil, France
[10] Univ Paris 05, Plateforme Paris Descartes Bioinformat, Paris, France
[11] Inst Cochin, Plateforme Genom, Paris, France
[12] Hop Cochin, AP HP, Serv Hematol Biol, Paris, France
[13] Hop St Louis, AP HP, Serv Hematol Senior, Paris, France
[14] Hop St Louis, AP HP, Lab Biostat & Epidemiol Clin INSERM UMR S 717, Paris, France
来源：
LEUKEMIA | 2018年 / 32卷 / 02期
关键词：
TRANSFUSION-DEPENDENT PATIENTS; 5Q DELETION; RISK MDS; ERYTHROPOIETIN; PLACEBO;
D O I：
10.1038/leu.2017.305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 562
页数：6
相关论文
共 50 条
  • [1] Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling
    Kerdivel, Gwenneg
    Chesnais, Virginie
    Becht, Etienne
    Toma, Andrea
    Cagnard, Nicolas
    Dumont, Florent
    Rousseau, Alice
    Fenaux, Pierre
    Chevret, Sylvie
    Chapuis, Nicolas
    Boeva, Valentina
    Fridman, Wolf-Herman
    Kosmider, Olivier
    Fontenay, Michaela
    BLOOD, 2017, 130
  • [2] Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling
    G Kerdivel
    V Chesnais
    E Becht
    A Toma
    N Cagnard
    F Dumont
    A Rousseau
    P Fenaux
    S Chevret
    N Chapuis
    V Boeva
    W H Fridman
    M Fontenay
    O Kosmider
    Leukemia, 2018, 32 : 558 - 562
  • [3] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [4] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [5] Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Guan, Yihong
    Nagata, Yasunobu
    Adema, Vera
    Hasipek, Metis
    Gerds, Aaron T.
    Carraway, Hetty E.
    Advani, Anjali S.
    Przychodzen, Bartlomiej P.
    Santini, Valeria
    Maciejewski, Jaroslaw P.
    Jha, Babal K.
    Nazha, Aziz
    BLOOD, 2018, 132
  • [6] Treating non-del 5q patients with lenalidomide
    Schiffer, C. A.
    LEUKEMIA RESEARCH, 2007, 31 : S9 - S10
  • [7] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
  • [8] Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
    Wang, Chen
    McGraw, Kathy L.
    McLemore, Amy F.
    Komrokji, Rami
    Basiorka, Ashley A.
    Al Ali, Najla
    Lancet, Jeffrey E.
    Padron, Eric
    Kosmider, Olivier
    Fontenay, Michaela
    Fenaux, Pierre
    List, Alan F.
    Sallman, David A.
    HAEMATOLOGICA, 2022, 107 (03) : 737 - 739
  • [9] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [10] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
12345